<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Amantadine</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Amantadine</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>
Amantadine is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Amantadine (brand names: Symmetrel, Gocovri, Osmolex ER) is a multifaceted pharmacological agent with a unique history and diverse clinical applications in [neurodegenerative diseases. Originally developed as an antiviral agent for influenza A in the 1960s, amantadine's antiparkinsonian properties were serendipitously discovered in 1968 when a patient with [parkinsons](/diseases/parkinsons-disease) experienced marked improvement in her parkinsonian symptoms while taking the drug for influenza prophylaxis ([Schwab et al., 1969](https://pubmed.ncbi.nlm.nih.gov/5769028/)). Since then, amantadine has become a cornerstone of [parkinsons](/diseases/parkinsons-disease) management, particularly as the only pharmacological agent with demonstrated efficacy in treating levodopa-induced dyskinesia (LID). [@hauser2023]
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Amantadine</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Amantadine</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>
Amantadine is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Amantadine (brand names: Symmetrel, Gocovri, Osmolex ER) is a multifaceted pharmacological agent with a unique history and diverse clinical applications in [neurodegenerative diseases. Originally developed as an antiviral agent for influenza A in the 1960s, amantadine's antiparkinsonian properties were serendipitously discovered in 1968 when a patient with [parkinsons](/diseases/parkinsons-disease) experienced marked improvement in her parkinsonian symptoms while taking the drug for influenza prophylaxis ([Schwab et al., 1969](https://pubmed.ncbi.nlm.nih.gov/5769028/)). Since then, amantadine has become a cornerstone of [parkinsons](/diseases/parkinsons-disease) management, particularly as the only pharmacological agent with demonstrated efficacy in treating levodopa-induced dyskinesia (LID). [@hauser2023]
Amantadine exerts its therapeutic effects through multiple mechanisms, including weak non-competitive antagonism of [nmda-receptor](/entities/nmda-receptor) receptor] receptors], enhancement of [dopamine](/entities/dopamine) release, inhibition of dopamine reuptake, and modulation of nicotinic acetylcholine receptors. This combination of dopaminergic and glutamatergic properties accounts for its dual efficacy against parkinsonian motor symptoms and levodopa-induced dyskinesia ([Hubsher et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22729544/); [Aranda-Abreu et al., 2021](https://pmc.ncbi.nlm.nih.gov/articles/PMC7901515/)). [@hubsher2012]
The primary mechanism underlying amantadine's anti-dyskinetic effects is non-competitive antagonism of [nmda-receptor](/entities/nmda-receptor) receptor]-type glutamate receptors]. Amantadine binds to the phencyclidine (PCP) site within the [nmda-receptor](/entities/nmda-receptor) receptor] receptor channel pore at therapeutically relevant concentrations (IC₅₀ ≈ 10–30 µM), blocking excessive [glutamate](/entities/glutamate)-mediated excitatory transmission in the [basal-ganglia](/brain-regions/basal-ganglia) ([Blanpied et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16115863/)). [@arandaabreu2021]
In [parkinsons](/diseases/parkinsons-disease), chronic [levodopa](/therapeutics/levodopa) treatment leads to maladaptive plasticity at corticostriatal glutamatergic synapses in the [striatum](/brain-regions/striatum), resulting in overactivity of the glutamatergic subthalamo-pallidal pathway. This glutamatergic overactivity is a key driver of levodopa-induced dyskinesia. By blocking [nmda-receptor](/entities/nmda-receptor) receptors, amantadine normalizes this aberrant glutamatergic transmission, reducing dyskinesia severity without compromising the antiparkinsonian benefits of levodopa ([Chase et al., 1998](https://pubmed.ncbi.nlm.nih.gov/9595981/); [Bhidayasiri & Truong, 2008](https://pubmed.ncbi.nlm.nih.gov/18625541/)). [@fda2023]
Amantadine enhances dopaminergic neurotransmission through multiple mechanisms: [@chen2020]
Amantadine acts as an agonist at the sigma-1 (σ₁) receptor, a chaperone protein located on the endoplasmic reticulum membrane. The σ₁ receptor modulates intracellular calcium signaling, mitochondrial function, and neuroprotection. Activation of σ₁ receptors by amantadine may contribute to its neuroprotective properties and its ability to modulate dopaminergic neurotransmission ([Peeters et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15541878/); [Aranda-Abreu et al., 2021](https://pmc.ncbi.nlm.nih.gov/articles/PMC7901515/)).
Amantadine is a negative allosteric modulator of nicotinic [acetylcholine](/entities/acetylcholine) receptors, specifically the α4β2 (IC₅₀ ≈ 3.4 µM) and α7 subtypes (IC₅₀ ≈ 6.5 µM). These nicotinic receptors are expressed in the [basal-ganglia](/brain-regions/basal-ganglia) and modulate dopamine release. The blockade of nicotinic receptors by amantadine may contribute to its effects on motor function and represents an additional mechanism through which the drug influences basal ganglia circuitry ([Matsubayashi et al., 1997](https://pubmed.ncbi.nlm.nih.gov/9126731/); [Aranda-Abreu et al., 2021](https://pmc.ncbi.nlm.nih.gov/articles/PMC7901515/)).
Amantadine exhibits weak anticholinergic activity, contributing to its mild beneficial effects on tremor and rigidity in Parkinson's Disease. However, these anticholinergic properties also underlie some of its adverse effects, including dry mouth, urinary retention, and confusion, particularly in elderly patients ([Hubsher et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22729544/)).
Gocovri (amantadine extended-release capsules) was FDA-approved in 2017 as the first drug specifically indicated for levodopa-induced dyskinesia in Parkinson's Disease:
Amantadine is the only approved pharmacological treatment for levodopa-induced dyskinesia (LID) in [parkinsons](/diseases/parkinsons-disease). LID affects approximately 40–50% of patients within 4–6 years of [levodopa](/therapeutics/levodopa) therapy initiation, and up to 90% after 10 years. Clinical evidence supporting amantadine's anti-dyskinetic efficacy includes:
Amantadine may be used as initial monotherapy in early Parkinson's Disease, particularly in younger patients with mild symptoms where delaying levodopa initiation is desired. Its modest dopaminergic effects provide symptomatic relief of bradykinesia, rigidity, and tremor, though the magnitude of benefit is generally less than that achieved with levodopa or [dopamine-agonists](/therapeutics/dopamine-agonists) ([Schwab et al., 1969](https://pubmed.ncbi.nlm.nih.gov/5769028/); [Pahwa et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16801660/)).
The extended-release formulation (Gocovri) is indicated as adjunctive treatment to levodopa/carbidopa in patients experiencing OFF episodes — periods when medication effects wear off and parkinsonian symptoms return. The bedtime dosing of Gocovri provides higher amantadine concentrations during morning hours, addressing the common problem of morning OFF periods and morning akinesia.
Amantadine has shown significant promise in accelerating functional recovery in patients with traumatic brain injury (TBI). A landmark randomized controlled trial demonstrated that amantadine (200–400 mg/day) significantly increased the rate of functional recovery in patients in vegetative or minimally conscious states during the 4-week treatment period. The mechanism is believed to involve both dopaminergic neuroactivation and [nmda-receptor](/entities/nmda-receptor) receptor modulation, promoting arousal and cognitive recovery ([Giacino et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22397651/)).
Amantadine is commonly used off-label for the treatment of fatigue in [multiple-sclerosis](/diseases/multiple-sclerosis) (MS), one of the most prevalent and disabling symptoms of the disease. While clinical trial evidence has been mixed, with some studies showing modest improvement in subjective fatigue measures, consensus guidelines from the German Multiple Sclerosis Society and the UK National Institute for Health and Care Excellence (NICE) recommend considering amantadine for MS-related fatigue. The TRIUMPHANT-MS randomized trial showed that amantadine produced improvement comparable to modafinil and methylphenidate ([Nourbakhsh et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33296408/)).
Though not formally approved for this indication, amantadine has been investigated for the management of chorea in [huntington-pathway](/mechanisms/huntington-pathway). Its [nmda-receptor](/entities/nmda-receptor) receptor antagonism may help modulate the excessive glutamatergic transmission that contributes to choreiform movements, though [VMAT2 inhibitors/therapeutics/vmat2 such as tetrabenazine and deutetrabenazine have become the preferred pharmacological treatments for Huntington's chorea.
Amantadine's serendipitous discovery as an antiparkinsonian agent exemplifies the role of clinical observation in drug repurposing. Its unique pharmacological profile — combining dopaminergic, glutamatergic, and nicotinic receptor modulation — makes it irreplaceable in the Parkinson's Disease treatment armamentarium, particularly for managing levodopa-induced dyskinesia.
Emerging research suggests that amantadine may possess neuroprotective properties independent of its symptomatic effects. Through σ₁ receptor agonism and [nmda-receptor](/entities/nmda-receptor) receptor modulation, amantadine may reduce [excitotoxicity](/mechanisms/excitotoxicity), modulate [neuroinflammation](/mechanisms/neuroinflammation), and promote neuroprotection via [bdnf](/proteins/bdnf) and [gdnf](/entities/gdnf) signaling pathways. However, definitive evidence of disease-modifying effects in Parkinson's Disease is lacking, and prospective clinical trials are needed ([Aranda-Abreu et al., 2021](https://pmc.ncbi.nlm.nih.gov/articles/PMC7901515/)).
Development of new extended-release formulations with improved pharmacokinetic profiles continues, aiming to optimize the balance between efficacy and tolerability while maintaining therapeutic drug concentrations throughout the day.
The study of Amantadine has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses: